scholarly journals Sulfonylurea antidiabetics are associated with lower risk of out‐of‐hospital cardiac arrest: Real‐world data from a population‐based study

2021 ◽  
Author(s):  
Talip E. Eroglu ◽  
Lixia Jia ◽  
Marieke T. Blom ◽  
Arie O. Verkerk ◽  
Harsha D. Devalla ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Real World ◽  
Lower Risk ◽  
Population Based ◽  
Real World Data ◽  
Population Based Study ◽  
World Data ◽  
Hospital Cardiac Arrest

Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1048-1048
Author(s):  
Wei Fang Dai ◽  
Jaclyn Marie Beca ◽  
Chenthila Nagamuthu ◽  
Ning Liu ◽  
Maureen E. Trudeau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Incremental Cost ◽  
Real World ◽  
Retrospective Cohort ◽  
Health Technology ◽  
Population Based ◽  
Net Benefit ◽  
Real World Data ◽  
World Data

1048 Background: Addition of P to T+chemo for MBC pts has been shown to improve overall survival (OS) in a pivotal randomized trial (hazard ratio [HR] = 0.66, 95% CI: 0.52, 0.84) (Baselga et al., NEJM 2012). In Canada, the manufacturer submission to the health technology assessment agency estimated that P produced 0.64 life years gained (LYG) with an incremental cost-effectiveness ratio (ICER) of $187,376/LYG over 10 years (CADTH-pCODR, 2013). This retrospective cohort analysis aims to determine the comparative real-world population-based effectiveness and cost-effectiveness of P among MBC pts in Ontario, Canada. Methods: MBC pts were identified from the Ontario Cancer Registry and linked to the New Drug Funding Program database to identify receipt of treatment between 1/1/2008 and 3/31/2018. Cases received P-T-chemo after universal public funding of P (Nov 2013) and controls received T-chemo before. Demographic (age, socioeconomic, rurality) and clinical (comorbidities, prior adjuvant treatments, prior breast cancer surgery, prior radiation, stage at diagnosis, ER/PR status) characteristics were identified from linked admin databases balanced between cases and controls using propensity score matching. Kaplan-Meier methods and Cox regressions accounting for matched pairs were used to estimate median OS and HR. 5-year mean total costs from the public health system perspective were estimated from admin claims databases using established direct statistical methods and adjusted for censoring of both cost and effectiveness using inverse probability weighting. ICERs and 95% bootstrapped CIs were calculated, along with incremental net benefit (INB) at various willingness-to-pay values using net benefit regression. Results: We identified 1,823 MBC pts with 912 cases and 911 controls (mean age = 55 years), of which 579 pairs were matched. Cases had improved OS (HR = 0.66; 95% CI: 0.57, 0.78), with median 3.4 years, compared to controls median OS of 2.1. P provided an additional 0.63 (95% CI: 0.48 – 0.84) LYG at an incremental cost of $196,622 (95% CI: $180,774, $219,172), with a mean ICER = $312,147/LYG (95% CI: $260,752, $375,492). At threshold of $100,000/LYG, the INB was -$133,632 (95% CI: -$151,525, -$115,739) with < 1% probability of being cost-effective. Key drivers of incremental cost increase between groups included drug and cancer clinic costs. Conclusions: The addition of P to T-chemo for MBC increased survival but at significant costs. The ICER based on direct real-world data was higher than the initial economic model due to higher total costs for pts receiving P. This study demonstrated feasibility to derive ICER from person-level real-world data to inform cancer drug life-cycle health technology reassessment.

scholarly journals Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries

2019 ◽  
Vol 6 (6) ◽  
pp. 347-355 ◽  
Author(s):  
Talip E Eroglu ◽  
Grimur H Mohr ◽  
Marieke T Blom ◽  
Arie O Verkerk ◽  
Patrick C Souverein ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
General Population ◽  
Calcium Channels ◽  
Cardiac Electrophysiology ◽  
Low Dose ◽  
Population Based ◽  
High Dose ◽  
Real World Data ◽  
Registration System ◽  
Hospital Cardiac Arrest

Abstract Aims Various drugs increase the risk of out-of-hospital cardiac arrest (OHCA) in the general population by impacting cardiac ion channels, thereby causing ventricular tachycardia/fibrillation (VT/VF). Dihydropyridines block L-type calcium channels, but their association with OHCA risk is unknown. We aimed to study whether nifedipine and/or amlodipine, often-used dihydropyridines, are associated with increased OHCA risk, and how these drugs impact on cardiac electrophysiology. Methods and results We conducted a case–control study with VT/VF-documented OHCA cases with presumed cardiac cause from ongoing population-based OHCA registries in the Netherlands and Denmark, and age/sex/index date-matched non-OHCA controls (Netherlands: PHARMO Database Network, Denmark: Danish Civil Registration System). We included 2503 OHCA cases, 10 543 non-OHCA controls in Netherlands, and 8101 OHCA cases, 40 505 non-OHCA controls in Denmark. To examine drug effects on cardiac electrophysiology, we performed single-cell patch-clamp studies in human-induced pluripotent stem cell-derived cardiomyocytes. Use of high-dose nifedipine (≥60 mg/day), but not low-dose nifedipine (&lt;60 mg/day) or amlodipine (any-dose), was associated with higher OHCA risk than non-use of dihydropyridines [Netherlands: adjusted odds ratios (ORadj) 1.45 (95% confidence interval 1.02–2.07), Denmark: 1.96 (1.18–3.25)] or use of amlodipine [Netherlands: 2.31 (1.54–3.47), Denmark: 2.20 (1.32–3.67)]. Out-of-hospital cardiac arrest risk of (high-dose) nifedipine use was not further increased in patients using nitrates, or with a history of ischaemic heart disease. Nifedipine and amlodipine blocked L-type calcium channels at similar concentrations, but, at clinically used concentrations, nifedipine caused more L-type calcium current block, resulting in more action potential shortening. Conclusion High-dose nifedipine, but not low-dose nifedipine or any-dose amlodipine, is associated with increased OHCA risk in the general population. Careful titration of nifedipine dose should be considered.

Long-term cognitive outcomes following out-of-hospital cardiac arrest: A population-based study

Neurology ◽  
2011 ◽  
Vol 77 (15) ◽  
pp. 1438-1445 ◽  
Author(s):  
F. J. Mateen ◽  
K. A. Josephs ◽  
M. R. Trenerry ◽  
M. D. Felmlee-Devine ◽  
A. L. Weaver ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Population Based ◽  
Cognitive Outcomes ◽  
Population Based Study ◽  
Hospital Cardiac Arrest

Factors associated with out-of-hospital cardiac arrest with pulseless electric activity: A population-based study

2016 ◽  
Vol 177 ◽  
pp. 129-137 ◽  
Author(s):  
Dennis T. Ko ◽  
Feng Qiu ◽  
Maria Koh ◽  
Paul Dorian ◽  
Sheldon Cheskes ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Electric Activity ◽  
Population Based ◽  
Population Based Study ◽  
Factors Associated ◽  
Hospital Cardiac Arrest

scholarly journals Monophasic versus biphasic defibrillation for pediatric out-of-hospital cardiac arrest patients: a nationwide population-based study in Japan

Critical Care ◽  
2012 ◽  
Vol 16 (6) ◽  
pp. R219 ◽  
Author(s):  
Seizan Tanabe ◽  
Hideo Yasunaga ◽  
Soichi Koike ◽  
Manabu Akahane ◽  
Toshio Ogawa ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Population Based ◽  
Population Based Study ◽  
Hospital Cardiac Arrest

Incidence and survival rate of bystander-witnessed out-of-hospital cardiac arrest with cardiac etiology in Osaka, Japan: a population-based study according to the Utstein style

Resuscitation ◽  
2003 ◽  
Vol 59 (3) ◽  
pp. 329-335 ◽  
Author(s):  
Tatsuya Nishiuchi ◽  
Atsushi Hiraide ◽  
Yasuyuki Hayashi ◽  
Toshifumi Uejima ◽  
Hiroshi Morita ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Survival Rate ◽  
Population Based ◽  
Population Based Study ◽  
Utstein Style ◽  
Hospital Cardiac Arrest

scholarly journals Fracture Risk Assessment With FRAX Using Real-World Data in a Population-Based Cohort From Israel

2017 ◽  
Vol 187 (1) ◽  
pp. 94-102 ◽  
Author(s):  
Inbal Goldshtein ◽  
Yariv Gerber ◽  
Sophia Ish-Shalom ◽  
Moshe Leshno
Keyword(s):  
Risk Assessment ◽  
Fracture Risk ◽  
Real World ◽  
Population Based ◽  
Fracture Risk Assessment ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document